Compare Quest Diagnostics Inc (DGX) vs PAGSEG Inc (PAGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs PAGSEG Inc — how do they compare? Quest Diagnostics Inc trades at $237.51 (market cap $26.21B), while PAGSEG Inc trades at $8.97 (market cap $2.48B). The key difference: Quest Diagnostics Inc is far larger — about 10.6× PAGSEG Inc's market cap, and PAGSEG Inc pays the higher dividend (11.7%). Which is the better fit depends on your goals.
| DGX | PAGS | |
|---|---|---|
Market Cap | $26.21B | $2.48B |
Sector | Health | Technology |
52-Week High | $238.50 | $12.00 |
52-Week Low | $173.49 | $8.38 |
Enterprise Value | $31.97B | $10.22B |
Dividend Yield | 1.45% | 11.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.99, up 0.15% on the day, near its 52-week high. The stock shows strong momentum with consecutive earnings beats in 2026, including Q2 EPS of $3.12 versus $2.82 expected. Revenue growth accelerated to $11.04 billion in 2025, with net income margin at 9.19%. Technical indicators signal a bullish trend, while analyst consensus is a $249.50 price target. Recent news highlights AI integration and raised 2026 outlook amid robust testing demand.
The outlook for DGX is positive, driven by earnings momentum, strategic partnerships, and healthcare demand. Investment opportunity lies in sustained growth and dividend yield, but risks include margin pressure from lower-margin deals and high debt levels. Valuation at a P/E of 25.21 requires continued execution to justify upside.
PAGS trades at $8.70, down 4.19% over 24 hours, reflecting recent bearish technical signals. The stock shows strong fundamentals with a P/E of 6.17 and net income margin of 10.4%, while Q2 2026 earnings beat expectations. Recent news highlights robust Q2 2026 results, including R$576 million recurring net income and growth in deposits and loans, per PRNewsWire on August 12, 2026.
The outlook is mixed; low valuations and analyst consensus of $11.45 price target suggest upside, but technical bearishness and CEO share sales pose risks. Investors may find value in earnings growth potential, though market volatility and competitive pressures require caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About PAGSEG Inc
PagSeguro Digital Ltd. is a leading provider of financial technology solutions in Brazil, primarily focused on e-commerce, face-to-face transactions, and financial services. The company's main offerings include PagBank, a digital banking platform, and PagSeguro, a suite of payment processing solutions that includes point-of-sale devices and online payment gateways. PAGS targets micro-merchants, small and medium-sized enterprises (SMEs), and consumers, aiming to democratize access to financial services in the country.
Read more on PAGS →
